Kindly MD (NAKA)
NASDAQ:NAKA
Want to see NAKA full AI Analyst Report?
Top Page
Kindly MD
(NASDAQ:NAKA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$5.00
▲(1823.08% Upside)
Action:Reiterated
Date:06/02/26
The score is primarily weighed down by weak financial performance—severe profitability pressure and sustained cash burn—followed by bearish technical signals with the stock trading below key moving averages. Valuation provides only limited support because losses (negative P/E) make earnings-based valuation less meaningful and there is no dividend yield provided.
Positive Factors
Revenue recovery
A >100% TTM revenue rebound signals meaningful demand recovery and product-market traction. Sustained top-line growth provides the structural basis to absorb fixed costs, achieve scale economies, and justify follow-on investment to drive durable margin improvement if management sustains revenue momentum.
Negative Factors
Deeply negative margins
Severely negative gross and net margins indicate the core business does not cover direct costs or operating expenses. This structural profitability gap will erode equity over time, constrain reinvestment, and requires meaningful business-model changes to restore sustainable earnings power.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue recovery
A >100% TTM revenue rebound signals meaningful demand recovery and product-market traction. Sustained top-line growth provides the structural basis to absorb fixed costs, achieve scale economies, and justify follow-on investment to drive durable margin improvement if management sustains revenue momentum.
Read all positive factors
Kindly MD (NAKA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$86.49M
Dividend YieldN/A
Average Volume (3M)30.98M
Price to Earnings (P/E)―
Beta (1Y)3.99
Revenue Growth58.66%
EPS Growth-47.90%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryFinancial - Capital Markets
Share Statistics
EPS (TTM)-29.55
Shares Outstanding17,402,140
10 Day Avg. Volume32,220,503
30 Day Avg. Volume30,978,537
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)87.61
P/FCF Ratio-6.72
Enterprise Value/Market Cap71.51
Enterprise Value/Revenue1.58K
Enterprise Value/Gross Profit-419.63
Enterprise Value/Ebitda-22.35
Forecast
1Y Price Target
$27.50Price Target Upside10476.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-8
Revenue Forecast (FY)$36.77M
Kindly MD Business Overview & Revenue Model
Company Description
Nakamoto Inc. develops and invests in a global portfolio of Bitcoin-native companies. It offers commercial and financial infrastructure for the capital markets. The company was formerly known as Kindly MD, Inc. and change its name to Nakamoto Inc....
How the Company Makes Money
null...
Kindly MD Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.92M | 1.82M | 2.72M | 3.77M | 3.79M | 2.50M |
| Gross Profit | -14.74M | -9.27M | -842.57K | 3.54M | 3.63M | 914.92K |
| EBITDA | -276.76M | -44.93M | -3.00M | -1.36M | -2.42M | 124.74K |
| Net Income | -289.97M | -52.23M | -3.62M | -1.62M | -2.54M | 149.34K |
Balance Sheet | ||||||
| Total Assets | 620.76M | 730.61M | 3.68M | 1.10M | 947.00K | 447.64K |
| Cash, Cash Equivalents and Short-Term Investments | 35.30M | 22.58M | 2.27M | 525.50K | 186.92K | 94.69K |
| Total Debt | 209.74M | 209.92M | 783.68K | 636.38K | 391.13K | 109.81K |
| Total Liabilities | 253.69M | 216.35M | 1.11M | 1.21M | 565.98K | 174.56K |
| Stockholders Equity | 367.07M | 514.26M | 2.57M | -108.41K | 381.01K | 273.09K |
Cash Flow | ||||||
| Free Cash Flow | -45.99M | -23.75M | -3.48M | -463.91K | -457.77K | 57.84K |
| Operating Cash Flow | -45.93M | -23.51M | -3.07M | -449.49K | -140.38K | 121.44K |
| Investing Cash Flow | -643.29M | -680.02M | -401.63K | -14.42K | -317.39K | -63.60K |
| Financing Cash Flow | 723.38M | 723.85M | 5.22M | 802.49K | 550.00K | -45.34K |
Kindly MD Technical Analysis
Negative
0.26
Price Trends
8.04
Negative
10.44
Negative
48.45
Negative
Market Momentum
-0.73
Positive
35.98
Neutral
38.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAKA, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 6.76, below the 50-day MA of 8.04, and below the 200-day MA of 48.45, indicating a bearish trend. The MACD of -0.73 indicates Positive momentum. The RSI at 35.98 is Neutral, neither overbought nor oversold. The STOCH value of 38.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAKA.
Kindly MD Risk Analysis
Kindly MD disclosed 135 risk factors in its most recent earnings report. Kindly MD reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kindly MD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $1.67B | 44.05 | 2.81% | 6.98% | 9.37% | 6.95% | |
60 Neutral | $1.67B | -15.37 | -24.79% | ― | ― | -18.14% | |
54 Neutral | $1.37B | -11.21 | -563.89% | ― | 550.00% | -107.04% | |
52 Neutral | $569.94M | ― | -23.00% | ― | 57.87% | 7.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.05B | -3.97 | -110.54% | ― | -86.41% | -45.44% | |
44 Neutral | $86.49M | -0.27 | -84.79% | ― | 58.66% | -47.90% |
* Healthcare Sector Average
NAKA
Kindly MD
4.97
-729.43
-99.32%
EYPT
EyePoint Pharmaceuticals
12.53
4.41
54.31%
INBX
Inhibrx Biosciences Inc
93.63
80.10
592.02%
RAPP
Rapport Therapeutics, Inc.
34.90
22.66
185.13%
SILA
Sila Realty Trust, Inc.
30.23
7.19
31.21%
BBNX
Beta Bionics, Inc.
12.79
-5.17
-28.79%
Kindly MD Corporate Events
Executive/Board ChangesDelistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Kindly MD Implements Reverse Stock Split and Governance Updates
Neutral
May 22, 2026
On May 21, 2026, Nakamoto Inc.’s board expanded from six to seven members and appointed Chief Investment Officer Tyler Evans as a Class II director through the 2026 annual meeting, without additional board compensation or committee roles. Th...
Shareholder MeetingsStock Split
Kindly MD Shareholders Approve Reverse Stock Split Authorization
Positive
May 12, 2026
On May 8, 2026, Nakamoto Inc. held a special meeting of stockholders at which 502,263,305 shares of common stock were represented in person or by proxy out of 690,018,254 entitled to vote, establishing a strong quorum for corporate governance deci...
Business Operations and StrategyRegulatory Filings and Compliance
Kindly MD Updates Indemnification Protections for Leadership
Neutral
May 7, 2026
On May 4, 2026, Nakamoto Inc.’s board approved a revised indemnification agreement for its directors and officers, replacing the prior form and aligning with protections already embedded in its charter and bylaws. The agreement commits the c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.